LeMaitre Vascular (LMAT) Expected to Announce Earnings on Tuesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.8070 per share and revenue of $71.4730 million for the quarter. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same period in the previous year, the company earned $0.48 EPS. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. On average, analysts expect LeMaitre Vascular to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $101.32 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The firm has a market capitalization of $2.32 billion, a P/E ratio of 37.39, a price-to-earnings-growth ratio of 2.81 and a beta of 0.52. LeMaitre Vascular has a 1-year low of $79.00 and a 1-year high of $118.01. The company’s 50-day moving average is $97.15 and its 200 day moving average is $99.65.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares of the company’s stock, valued at $401,143. The trade was a 43.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridget A. Ross sold 5,044 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the transaction, the director owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several institutional investors have recently bought and sold shares of LMAT. Royal Bank of Canada lifted its holdings in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after purchasing an additional 1,735 shares during the last quarter. AQR Capital Management LLC grew its stake in LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after buying an additional 7,445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in LeMaitre Vascular by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock worth $1,013,000 after buying an additional 539 shares during the last quarter. Millennium Management LLC increased its position in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after buying an additional 55,804 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LMAT. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Finally, Barrington Research restated an “outperform” rating and issued a $120.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.